Discovering Potential Drug Targets and Biomarkers for EEF1AKMT2

Target Name: EEF1AKMT2

NCBI ID: G399818

EEF1AKMT2

Discovering Potential Drug Targets and Biomarkers for EEF1AKMT2

EEF1AKMT2, also known as EFMT2_HUMAN, is a protein that is expressed in various tissues of the human body. It is a member of the EEF1A family of proteins, which are known for their role in intracellular signaling pathways. One of the EEF1A proteins, EEF1AKMT2, has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The EEF1A family of proteins is characterized by the presence of a unique N-terminal domain called the EEF1A-specific domain. This domain is known to be involved in the formation of a protein-protein interaction network and in the regulation of cellular signaling pathways. EEF1A-specific domains can be found in various proteins, including EEF1AKMT2, which is known to be a 21-kDa protein that is expressed in various tissues of the human body.

One of the unique features of EEF1AKMT2 is its ability to interact with other proteins. This interaction is mediated by the protein's N-terminal domain, which contains a conserved leucine residue that is known to be involved in protein-protein interactions. The leucine residue is important for the formation of a stable interaction between EEF1AKMT2 and other proteins, which allows the protein to function as a potential drug target or biomarker.

In recent years, researchers have been interested in exploring the potential applications of EEF1AKMT2 as a drug target or biomarker. One of the main reasons for this interest is the protein's expression in various tissues of the human body, which makes it a potential biomarker for several diseases. For example, EEF1AKMT2 has been shown to be expressed in a variety of tissues, including brain, heart, and muscle. This makes it a potential biomarker for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a biomarker, EEF1AKMT2 has also been identified as a potential drug target for several diseases. One of the main reasons for this interest is the protein's involvement in intracellular signaling pathways. As mentioned earlier, EEF1AKMT2 is a member of the EEF1A family of proteins, which are known for their role in intracellular signaling pathways. This suggests that EEF1AKMT2 may be involved in the regulation of cellular signaling pathways, including those that are responsible for maintaining cellular homeostasis and promoting cell survival.

One of the potential drug targets for EEF1AKMT2 is the regulation of cell death. Cancer cells are known to have the ability to escape the effects of cellular signaling pathways, including those that promote cell death. This is a major problem for cancer researchers, as it is difficult to develop effective therapies that can target cancer cells without also harming healthy cells. However, EEF1AKMT2 may be a potential solution to this problem. By targeting the regulation of cell death, researchers may be able to develop therapies that specifically target cancer cells while minimizing the effects on healthy cells.

Another potential drug target for EEF1AKMT2 is the regulation of inflammation. Chronic inflammation is a major problem for both healthy and diseased tissues, as it can contribute to a variety of diseases, including heart disease, autoimmune disorders, and neurodegenerative diseases. EEF1AKMT2 may be involved in the regulation of inflammation by promoting the production of pro-inflammatory cytokines. This suggests that EEF1AKMT2 may be a potential drug target for diseases that are characterized by chronic inflammation, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD).

In conclusion, EEF1AKMT2 is a protein that is expressed in various tissues of the human body and has been identified as a potential drug target or biomarker for several diseases. Its unique N-terminal domain, which is involved in protein-protein interaction

Protein Name: EEF1A Lysine Methyltransferase 2

Functions: Protein-lysine methyltransferase that selectively catalyzes the trimethylation of EEF1A at 'Lys-318'

The "EEF1AKMT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1AKMT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets